ResMed CEO exercises options, sells 4,991 shares

ResMed Inc. Chairman and CEO Michael J. Farrell exercised options to acquire 4,991 shares of ResMed common stock at $146.34 per share, then sold 4,991 shares at a weighted average price of $251.0322 per share.

Rhea-AI Filing Summary

ResMed Inc. Chairman and CEO Michael J. Farrell exercised options to acquire 4,991 shares of ResMed common stock at $146.34 per share, then sold 4,991 shares at a weighted average price of $251.0322 per share. The filing notes the sale was conducted under a Rule 10b5-1 trading plan adopted on October 31, 2024. After these transactions, he holds 466,223 shares directly and 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust.

Insider Trade Summary 10b5-1

Exercise and Sale: 4,991 shares ($523K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Farrell Michael J.

Role Chairman and CEO

Sold 4,991 shs ($1.25M)

Approx. gross sale proceeds $1.25M

Approx. exercise cost $730K

Approx. pre-tax spread $523K

Type	Security	Shares	Price	Value
Exercise	ResMed Common Stock Options	4,991	$0.00	$0.00
Exercise	ResMed Common Stock	4,991	$146.34	$730K
Sale	ResMed Common Stock	4,991	$251.0322	$1.25M
holding	ResMed Common Stock	--	--	--

Holdings After Transaction: ResMed Common Stock Options — 39,930 contracts (Direct); ResMed Common Stock — 466,223 shares (Direct); ResMed Common Stock — 2,090 shares (Indirect, Lisette and Michael Farrell Family Trust)

Footnotes (3)

1. F1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
2. F2. This transaction was executed in multiple trades at prices ranging from $246.83 - $253.09. The price reported above reflects the weighted average sale price.
3. F3. Represents date options first become exercisable. Options vest 1/3 per year.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/11/2026 - 08:29 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farrell Michael J.

(Last) (First) (Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	03/09/2026		M(1)		4,991	A	$146.34	471,214	D
ResMed Common Stock	03/09/2026		S(1)		4,991	D	$251.0322(2)	466,223	D
ResMed Common Stock								2,090	I	Lisette and Michael Farrell Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
ResMed Common Stock Options	$146.34	03/09/2026		M(1)			4,991	11/11/2020(3)	11/21/2026	ResMed Common Stock	4,991	$0	39,930	D

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

2. This transaction was executed in multiple trades at prices ranging from $246.83 - $253.09. The price reported above reflects the weighted average sale price.

3. Represents date options first become exercisable. Options vest 1/3 per year.

	/s/ Michael J. Farrell, Chairman and CEO	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.